Markets:

Overview

News

Currencies

International

Treasuries

Exact Sciences Corporation - Common Stock (NQ:EXAS)

103.18 +0.52 (+0.51%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Exact Sciences Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

The Era of the Titans: Q4 2025 Mega-Deal Surge and the 2026 Economic Map

February 06, 2026

As of February 6, 2026, the global financial landscape is still reverberating from a historic tectonic shift that occurred in the final months of last year. In the fourth quarter of 2025, the M&A...

Via MarketMinute

Topics Artificial Intelligence Economy

1 Growth Stock to Stash and 2 We Avoid

February 05, 2026

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who...

Via StockStory

Topics Climate Change

The Best Dividend King to Buy With $150 ↗

February 02, 2026

The stock is near its 52-week low.

Via The Motley Fool

Exact Sciences Stock Soars To 4-Year High Even As Wall Street Piles On Downgrades After Abbott Deal — Retail Traders Take Profits ↗

November 20, 2025

Via Stocktwits

Boston Scientific’s $14.5 Billion Stroke of Genius: Consolidation Heats Up in the Medtech Arms Race

February 02, 2026

In a move that has sent shockwaves through the healthcare sector, Boston Scientific (NYSE:BSX) has announced a definitive agreement to acquire Penumbra (NYSE:PEN) for approximately $14.5 billion. The...

Via MarketMinute

Topics Artificial Intelligence

3 Reasons to Buy This Dividend King After Its Steep Sell-Off ↗

January 26, 2026

Investors' reaction to this Dividend King's Q4 revenue miss was overdone.

Via The Motley Fool

Topics Earnings

Abbott Laboratories Shares Plunge 10% Following Q4 Revenue Miss and Diagnostics Weakness

January 22, 2026

Abbott Laboratories (NYSE: ABT) saw its stock price tumble by nearly 10% in early trading on January 22, 2026, following the release of its fourth-quarter 2025 financial results. Despite meeting...

Via MarketMinute

Topics Economy

Abbott Shares Slump as Revenue Miss and Exact Sciences Acquisition Jitters Overshadow Earnings Beat

January 22, 2026

Abbott Laboratories (NYSE: ABT) saw its shares retreat by 5.8% in early trading on Thursday, January 22, 2026, following the release of its fourth-quarter financial results. Despite delivering an...

Via MarketMinute

Topics Earnings Economy

$5.1 Trillion Global Surge: CEO Confidence Ignites New Era of M&A Transformation

January 19, 2026

The global Mergers and Acquisitions (M&A) market staged a historic comeback in 2025, with total deal value reaching a staggering $5.1 trillion. This resurgence represents a 44% year-over-year increase,...

Via MarketMinute

Topics Artificial Intelligence Economy Initial Public Offering

The Great Diagnostic Consolidation: How a $25.7 Billion Mega-Deal Ignited a 150% Surge in Healthcare M&A

January 14, 2026

As 2026 begins, the healthcare sector is undergoing its most profound transformation in decades. Driven by a relentless push toward "precision medicine" and the industrialization of artificial...

Via MarketMinute

Topics Artificial Intelligence

GRAIL Surges as Canaccord Genuity Sets Ambitious $105 Price Target Following Robust 2025 Growth

January 13, 2026

In a resounding vote of confidence for the future of multi-cancer early detection (MCED), Canaccord Genuity reiterated its "Buy" rating for GRAIL (Nasdaq: GRAL) on Tuesday, January 13, 2026, setting an...

Via MarketMinute

Adaptive Biotechnologies Surges as Preliminary 2025 Results Signal a Turning Point in MRD Commercialization

January 13, 2026

Shares of Adaptive Biotechnologies (NASDAQ: ADPT) soared on Tuesday, January 13, 2026, after the life sciences company announced preliminary fourth-quarter and full-year 2025 financial results that...

Via MarketMinute

Biodesix Shares Rocket 42% on Record FY2025 Results and Path to Profitability

January 12, 2026

On January 12, 2026, the diagnostic sector witnessed a seismic shift as shares of Biodesix (Nasdaq: BDSX) surged more than 40% in early trading, following the release of preliminary full-year 2025...

Via MarketMinute

Topics Artificial Intelligence Death

3 Mid-Cap Stocks We Steer Clear Of

January 08, 2026

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract...

Via StockStory

Stay updated with the stocks that are on the move in today's after-hours session. ↗

January 07, 2026

Via Chartmill

1 High-Flying Stock on Our Watchlist and 2 We Question

January 04, 2026

"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated...

Via StockStory

3 Unpopular Stocks We Steer Clear Of

December 30, 2025

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps...

Via StockStory

1 Healthcare Stock for Long-Term Investors and 2 We Avoid

December 10, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Those leading the charge have realized strong financial performance, and over the past six months, the...

Via StockStory

Topics Stocks

3 Overrated Stocks That Concern Us

December 03, 2025

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro...

Via StockStory

Here's Why Grail Soared, Again, in November ↗

December 02, 2025

A combination of operational improvements and developments at its key rival bolstered the stock recently.

Via The Motley Fool

This Top Dividend King Just Became an Even Better Buy ↗

November 30, 2025

The healthcare leader wants to make waves in a potentially highly lucrative market.

Via The Motley Fool

Unusual volume stocks are being observed in Monday's session. ↗

November 24, 2025

Let's explore the current happenings on the US markets on Monday. Below, you'll find the stocks exhibiting unusual volume in today's session.

Via Chartmill

Q3 Earnings Highs And Lows: Exact Sciences (NASDAQ:EXAS) Vs The Rest Of The Immuno-Oncology Stocks

November 23, 2025

As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the immuno-oncology industry, including Exact Sciences (NASDAQ:EXAS) and its peers.

Via StockStory

Topics Artificial Intelligence

Biggest Stock Movers Today, Nov. 20: PACS, BBWI, & More ↗

November 20, 2025

On a big day for tech stocks, some other less well-known companies saw even larger moves.

Via The Motley Fool

Topics Artificial Intelligence Stocks

Why Exact Sciences Rallied Over 50% This Week ↗

November 20, 2025

The company received a buyout offer from Abbot Labs.

Via The Motley Fool

Why Exact Sciences Stock Surged Today ↗

November 20, 2025

A healthcare giant covets the cancer screening leader's technology.

Via The Motley Fool

Tech Stocks Fall Despite Nvidia's Beat, Walmart Jumps 6%: What's Moving Markets Thursday? ↗

November 20, 2025

Nvidia Corp. (NASDAQ:NVDA) delivered another blockbuster quarter and raised its outlook, but even that wasn't enough to lift Wall Street on Thursday.

Via Benzinga

Nutex Health Posts Strong Q3 Results, Joins PACS Group, Walmart, Cerence And Other Big Stocks Moving Higher On Thursday ↗

November 20, 2025

Via Benzinga

Abbott's $21 Billion Exact Sciences Buyout Reshapes Cancer Diagnostics ↗

November 20, 2025

Abbott will acquire Exact Sciences for $21 billion, adding Cologuard and expanding its diagnostics portfolio as analysts highlight growth and valuation momentum.

Via Benzinga

Abbott To Acquire Exact Sciences For Up To $23B ↗

November 20, 2025

Under the deal, Exact Sciences shareholders will receive $105 per common share in cash.

Via Stocktwits

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Exact Sciences Corporation - Common Stock (NQ:EXAS)

Headline News about Exact Sciences Corporation - Common Stock

Starting at $3.75/week.

Subscribe Today